Benefit of Anti-hepatitis B Immunoglobulin(HBIG) Monotherapy Compared to HBIG Combined with Entecavir in Long Term Renal Function

被引：0

作者：

Lee, Jae Geun ^{[1
]}

Kim, Deok Gie ^{[1
]}

Lee, Jung Jun ^{[2
]}

Kim, Sung Hoon ^{[3
]}

Song, Seung Hwan ^{[4
]}

Lee, Jee Youn ^{[1
]}

Kim, Myoung Soo ^{[1
]}

Ju, Man Ki ^{[1
]}

Choi, Gi Hong ^{[1
]}

Choi, Jin Sub ^{[1
]}

Kim, Soon Il ^{[1
]}

Joo, Dong Jin ^{[1
]}

机构：

[1] Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea

[2] CHA Bundang Med Ctr, Dept Surg, Seoul, South Korea

[3] Yonsei Univ, Dept Surg, Wonju Coll Med, Wonju, South Korea

[4] Ewha Womans Univ, Dept Surg, Coll Med, Seoul, South Korea

来源：

TRANSPLANTATION | 2018年 / 102卷

关键词：

D O I：

10.1097/01.tp.0000542742.66921.33

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

400.8

引用

页码：S127 / S127

页数：1

共 50 条

[41] A PHARMACIST DELIVERED STRATIFIED CONVERSION PROTOCOL FROM HEPATITIS B IMMUNOGLOBULIN (HBIG) TO TENOFOVIR OR ENTECAVIR IS EFFICACIOUS, SAFE AND COST-EFFECTIVE FOR PREVENTION OF RECURRENCE OF HEPATITIS B VIRUS (HBV) IN LIVER TRANSPLANT (LT) RECIPIENTS
Knighton, S.
Agarwal, K.
Heneghan, M.
O'Grady, J.
Bruce, M.
Carey, I.
Heaton, N.
Suddle, A.
GUT, 2011, 60 : A35 - A36
[42] LONG-TERM EFFICACY OF NUCLEOS(T)IDE ANALOGUES (NA) PLUS LIMITED DURATION HEPATITIS B IMMUNOGLOBULIN (HBIG) IN THE PREVENTION OF HEPATITIS B VIRUS (HBV) RECURRENCE POST-LIVER TRANSPLANTATION (LT)
Chung, Chan Y.
Freise, Christopher E.
Yao, Francis Y.
Peters, Marion G.
Terrault, Norah
HEPATOLOGY, 2010, 52 (04) : 868A - 869A
[43] Early Switching to Subcutaneous Anti-Hepatitis B Virus Immunoglobulins (HBIg) after Liver Transplantation: 6-Month Results of a Single-Center Study.
De Simone, Paolo
Carrai, Paola
Ducci, Juri
Coletti, Laura
Balzano, Emanuele
Filipponi, Franco
LIVER TRANSPLANTATION, 2012, 18 : S222 - S222
[44] Long Term Outcomes of Entecavir Monotherapy after Liver Transplantation for Hepatitis B-5 Years Data
Wong, Tiffany C. L.
Fung, James Y. Y.
Chan, M. Y.
Chok, Kenneth S. H.
Cheung, T. T.
Chan, Albert C. Y.
Dai, W. C.
Chan, S. C.
Lo, C. M.
TRANSPLANTATION, 2015, 99 : 102 - 103
[45] Long-term consequences of stopping HBIG and/or nucleotide analogues in liver transplant recipients administered hepatitis B vaccination to prevent HBV reinfection
Duan, Bin-Wei
Tian, Lan-Tian
Lin, Dong-Dong
Zhang, Jing
Guo, Qing-Liang
Wu, Ju-Shan
Zeng, Dao-Bing
Lu, Shi-Chun
JOURNAL OF VIRAL HEPATITIS, 2019, 26 : 85 - 89
[46] Long-term combination HBIG and lamivudine is highly effective in preventing recurrent hepatitis B in orthotopic liver transplant (OLT) recipients.
Han, SH
Martin, P
Markowitz, J
Holt, C
Artinian, L
Kunder, G
Goldstein, LI
Goss, J
Seu, P
Busuttil, RW
HEPATOLOGY, 1998, 28 (04) : 222A - 222A
[47] The pharmacokinetic profile of low dose intramuscular (IM) hepatitis B immune globulin (HBIG) in long-term HBV liver transplant recipients.
Yoshida, EM
Guy, MW
Ensom, MM
Nobel, MA
Partovi, N
HEPATOLOGY, 2000, 32 (04) : 292A - 292A
[48] Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study
Liu, Ying
Ho, Wai I.
Deng, Feiwen
Peng, Siwei
Lau, Wan Yee
Chen, Huanwei
TRANSPLANTATION PROCEEDINGS, 2021, 53 (05) : 1700 - 1706
[49] Anti-hepatitis B virus treatment guided by long-term virus kinetics stepwise tracing
Yang, Jin
Cai, Ting
Lou, Guo-Qiang
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (06) : 1008 - 1016
[50] Long-Term Outcomes of Entecavir Monotherapy for Chronic Hepatitis B After Liver Transplantation: Results up to 8 Years
Fung, James
Wong, Tiffany
Chok, Kenneth
Chan, Albert
Cheung, Tan-To
Dai, Jeff Wing-Chiu
Sin, Sui-ling
Ma, Ka-Wing
Ng, Kelvin
Ng, Kevin Tak-Pan
Seto, Wai-Kay
Lai, Ching-Lung
Yuen, Man-Fung
Lo, Chung-Mau
HEPATOLOGY, 2017, 66 (04) : 1036 - 1044

← 1 2 3 4 5 →